Abstracts tagged "Lupus nephritis"

Abstract Number: 754 • 2015 ACR/ARHP Annual Meeting
Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide
Alexandra Audemard-Verger¹, Nicolas Martin Silva², Céline Verstuyft³, Nathalie Costedoat-Chalumeau⁴, Aurélie Hummel⁵, Véronique Le Guern⁴, Karim Sacre⁶, Olivier Meyer⁷, Eric Daugas⁸, Cecile Goujard⁹, Audrey Sultan², Thierry Lobbedez², Lionel Galicier¹⁰, Jacques Pourrat¹¹, Claire Le Hello², Michel Godin¹², Remy Morello², Marc Lambert¹³, Eric Hachulla¹³, Philippe Vanhille¹⁴, Guillaume Queffeulou¹⁵, Jacques Potier¹⁵, Jean Jacques Dion¹⁶, P Bataille¹⁷, Dominique Chauveau¹⁸, Guillaume Moulis¹⁹, Dominique Farge²⁰, Pierre Duhaut²¹, Bernadette Saint Marcoux²², Alban Deroux²³, Jennifer Manuzak²⁴, Camille Francès²⁵, Olivier Aumaître²⁶, Holy Bezanahary²⁷, Laurent Becquemont²⁸ and Boris Bienvenu²⁹, ¹Internal Medicine, CHU Caen, caen, France, ²CHU Caen, caen, France, ³Pharmacology, Hopital Bicêtre, Le Kremlin Bicêtre, France, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Necker, paris, France, ⁶Internal Medicine, Hospital Bichat, Paris, France, ⁷Rheumatology, Hopital Bichat, Paris, France, ⁸Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, ⁹Bichat, Paris, France, ¹⁰Clinical Immunology, St Louis Hospital, Paris, France, ¹¹Nephrology, Rangeuil Hospital, Paris, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Lille, Lille, France, ¹⁴Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, Valenciennes, France, ¹⁵Ch Cherbourg, Cherbourg, France, ¹⁶Ch Charleville Mezeiere, Charleville Mezeiere, France, ¹⁷Ch Boulogne sur Mer, Boulogne sur Mer, France, ¹⁸CH Toulouse, Toulouse, France, ¹⁹CHU Purpan, Toulouse, France, ²⁰Internal Medicine, Hopital St Louis, Paris, France, ²¹Department of Internal Medicine and RECIF, CHU Amiens, Amiens, France, ²²CH Aulnay sous Bois, Aulnay sous Bois, France, ²³Internal Medicine, CHU Grenoble, Grenoble, France, ²⁴Institut Cochin, Paris, France, ²⁵Dermatology Service, Tenon Hospital, Paris, France, ²⁶Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²⁷Internal Medicine, University Hospital of Limoges, Limoges, France, ²⁸KB, Paris, France, ²⁹Internal Medicine, Hospital Caen, Caen, France
Background/Purpose: Cyclophosphamide (CYC) is effective in inducing remission of lupus nephritis (LN). CYC, as a pro-drug, requires bioactivation through multiple hepatic cytochrome P450s and glutathione…
Abstract Number: 1067 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Anna R. Broder¹, Candace H. Feldman², Anand Kumthekar³, Michail Alevizos⁴, Hongshu Guan⁵, Medha Barbhaiya⁶ and Karen H. Costenbader⁷, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Internal Medicine, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest that males with lupus nephritis (LN) may have worse outcomes than females. However, the majority of these studies, are from tertiary-care…
Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting
Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis
Jeffrey Hampton¹, Nicholas A. Young², Sudha Agarwal³, Saba Aqel³, Kendra Jones³, Lai-Chu Wu^2,4, Nicole Powell⁵, John Sheridan⁵, Michael Bruss³ and Wael N. Jarjour², ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage. Our group has previously shown that moderate daily exercise reduces systemic inflammation…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting
Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Angela Pakozdi¹, Ravindra Rajakariar², Muhammad Magdi Yaqoob² and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…
Abstract Number: 1814 • 2015 ACR/ARHP Annual Meeting
Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
Jin Young Moon, Hyun Mi Kwon, Eun Young Ahn, Jin Kyun Park, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Treatment of lupus nephritis requires aggressive immunosuppressive drugs which includes high dose glucocorticoids. Immunosuppressive treatment is a risk factor for opportunistic infections such as…
Abstract Number: 2016 • 2015 ACR/ARHP Annual Meeting
Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging
Premasany Kanapathippillai, Sayed Esmaeil Dorraji and Kristin A Fenton, RNA and Molecular Pathology, UIT, The Artic University of Norway, Tromso, Norway
Background/Purpose: The formation of tertiary lymphoid structures (TLS) are known to occur during the development of several diseases, including systemic lupus erythematosus (SLE), but in…
Abstract Number: 2508 • 2015 ACR/ARHP Annual Meeting
Adherence to ACR Guidelines in the Management of Lupus Nephritis – a Quality Improvement Initiative
Erik Anderson¹, Matthew Abramson¹, Sanjay Godhwani², Yaqi Xue³, Jie Yang³ and Heidi Roppelt⁴, ¹Internal Medicine, Stony Brook Hospital, Stony Brook, NY, ²Medicine/Rheumatology, Stony Brook Medicine, Setauket, NY, ³Stony Brook University, Stony Brook, NY, ⁴Rheumatology, SUNY Stony Brook Unversity Hospital, East Setauket, NY
Background/Purpose: Lupus nephritis not only decreases survival, but also its costs are substantial, likely due in part to deficits in care (Carls et al.,…
Abstract Number: 2900 • 2015 ACR/ARHP Annual Meeting
Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis
Amy Sandford¹, Malvika Gulati², Ademola Oliatan³, Angela Pakozdi², Ravindra Rajakariar⁴, Andrea Cove-Smith⁴ and Dev Pyne², ¹Barts Health NHS trust, London, United Kingdom, ²Rheumatology, Barts Health NHS Trust, London, United Kingdom, ³Barts Health NHS Trust, London, United Kingdom, ⁴Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Recently phospholipase A2 receptor 1 (PLA2R1) has been found to be the antigenic target for primary membranous nephropathy (pMN) (1). Circulating anti-PLA2R1 autoantibody can…
Abstract Number: 2905 • 2015 ACR/ARHP Annual Meeting
Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis
Yasuhiro Katsumata, Hirokazu Nishina, Masanori Hanaoka, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Renal Disease Subcommittee of the American College of Rheumatology (ACR) Ad Hoc Committee on Systemic Lupus Erythematosus (SLE) has recommended the urinary protein level…
Abstract Number: 961 • 2014 ACR/ARHP Annual Meeting
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study
John G. Hanly for the Systemic Lupus International Collaborating Clinics¹, Aidan O'Keeffe², Li Su³, Murray B. Urowitz⁴, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha R Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, Joan T. Merrill¹¹, David A. Isenberg¹², Anisur Rahman¹³, Ellen M. Ginzler¹⁴, Paul Fortin¹⁵, Dafna D. Gladman⁴, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Barri Fessler²³, Kristjan Steinsson²⁴, Ola Nived²⁵, Gunnar Sturfelt²⁵, Susan Manzi²⁶, Munther A. Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Manuel Ramos-Casals³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Thomas Stoll³³, Murat Inanc³⁴, Kenneth C. Kalunian³⁵, Diane L. Kamen³⁶, Peter Maddison³⁷, Christine A. Peschken³⁸, Søren Jacobsen³⁹, Anca Askanase⁴⁰, Jill P. Buyon⁴¹, Chris Theriault⁴², Kara Thompson⁴² and Vernon Farewell³, ¹Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, ²MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, ⁹Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ¹⁰Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹³Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁴Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁵Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ¹⁶Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁹Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²⁰Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁴Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, ²⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁷Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²⁹Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ³¹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³²Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³³Kantonsspital Geissbergstr, Schaffhausen, Switzerland, ³⁴Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, ³⁵UCSD School of Medicine, La Jolla, CA, ³⁶Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ³⁷Ysbyty Gwynedd Bangor, North Wales, United Kingdom, ³⁸Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Columbia University Medical Center, New York, NY, ⁴¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴²Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Improved immunosuppressive therapies have changed the treatment of lupus nephritis (LN) over the past decade. We examined the outcome of LN with current standard…
Abstract Number: 2990 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study
Javier Merayo-Chalico¹, Elia Apodaca², Ana Barrera-Vargas³, Jorge Alcocer-Varela³ and Diana Gómez-Martín³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is a well-known but rare complication in systemic lupus erythematosus (SLE) patients (
Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting
Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010
Eric Y Yen¹, Magda Shaheen², Jennifer MP Woo³, Deborah K. McCurdy⁴ and Ram Raj Singh⁵, ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CA, ³UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁵Medicine, UCLA Division of Rheumatology, Los Angeles, CA
Title: Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose: Many epidemiologic studies of systemic…
Abstract Number: 2738 • 2014 ACR/ARHP Annual Meeting
Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis
Ernesto J. Muñoz-Elías¹, Kayla Norton¹, John B. Grigg¹, Liz Bromley¹, David W. Peckham¹, Eric J. Tarcha¹, Jared Odegard², James Qin², Megan Yuasa³, Anne Stevens⁴, Wayel H. Abdulahad⁵, Galina Schmunk⁶, K. George Chandy⁶ and Shawn P. Iadonato¹, ¹Kineta Inc., Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Physiology, Biophysics, and Surgery, UC Irvine, Irvine, CA
Background/Purpose: The voltage-gated potassium channel Kv1.3 is a novel target for the treatment of autoimmune disorders including psoriatic and rheumatic diseases. ShK-186 is an exquisitely specific,…
Abstract Number: 962 • 2014 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis
Jasvinder A. Singh¹, Alomgir Hossain², Ahmed Kotb² and George Wells³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare the risk of serious infections of immunosuppressive medications used for the treatment of lupus nephritis. Methods We performed an up to date…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].